Miravo Healthcare™ Announces 2020 and Fourth Quarter Results

 – Fiscal Year 2020 Adjusted Total Revenue – $71.0 million –
Fiscal Year 2020 Adjusted EBITDA – $28.4 million –
Blexten Canadian Prescriptions Increased 35% Year-Over-Year –
Cambia Canadian Prescriptions Increased 17% Year-Over-Year –


Miravo to Host Conference Call/Audio Webcast March 8th at 11:00 a.m. ET

Mississauga, Ontario, Canada – March 8, 2021 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months and year ended December 31, 2020.  For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Consolidated Financial Statements for the three months and year ended December 31, 2020 which are available on the Company’s website (www.miravohealthcare.com).  All figures are in Canadian dollars, unless otherwise noted.
See more….